Chen Yang, Zhu Hong, Xu Feng, Cao Yidan, Gu Xingting, Wan Yuming, Gou Hongfeng
Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu, Sichuan 610041, China.
Gastroenterol Res Pract. 2016;2016:3062547. doi: 10.1155/2016/3062547. Epub 2016 Jul 5.
We performed a retrospective analysis of 21 patients with primary gastric squamous cell carcinoma (PGSCC) who were admitted to our hospital from October 2008 to October 2014. The median age was 67 years and male predominance was observed, the most common tumor locations were the upper third of the stomach, most of the clinical manifestations were identical to those of other types of gastric tumors, and the tumor cells had positive immunoreactivity for p63 and CK5/6. In terms of treatments, surgery (R0 resection) is the main treatment; the effect of other treatments is unclear. The median survival time for the surgery group and nonsurgery group was 46 and 4.5 months, respectively. Probably due to limited number of cases, no significant difference in median survival time was observed between the surgery alone group and the surgery plus adjuvant therapy group (46 versus 51 months, P = 0.310). A standard chemotherapy regimen for this disease has not yet been established; the choice of its chemotherapy regimens tends to follow the principle of the treatment of gastric adenocarcinoma or esophageal cancer. PGSCC generally had a poor prognosis, and early detection, early diagnosis, and early surgical treatment are beneficial to patients.
我们对2008年10月至2014年10月期间收治于我院的21例原发性胃鳞状细胞癌(PGSCC)患者进行了回顾性分析。中位年龄为67岁,男性居多,最常见的肿瘤部位是胃的上三分之一,大多数临床表现与其他类型的胃肿瘤相同,肿瘤细胞对p63和CK5/6呈免疫反应阳性。在治疗方面,手术(R0切除)是主要治疗方法;其他治疗方法的效果尚不清楚。手术组和非手术组的中位生存时间分别为46个月和4.5个月。可能由于病例数有限,单纯手术组和手术加辅助治疗组之间的中位生存时间未观察到显著差异(46个月对51个月,P = 0.310)。该疾病的标准化化疗方案尚未确立;其化疗方案的选择倾向于遵循胃腺癌或食管癌的治疗原则。PGSCC总体预后较差,早期发现、早期诊断和早期手术治疗对患者有益。